IRB Advisor – June 1, 2013
June 1, 2013
View Issues
-
Consent form specialists assist investigators and board members
Experts say IRBs spend much of their time discussing informed consent issues and nuances, and yet this is the area cited most often in recent regulatory letters sent to research institutions. -
OHRP letters focus on informed consent issues
The University of Alabama at Birmingham (UAB) was the most recent in a small list of institutions that received letters of determination from the Office for Human Research Protections (OHRP) of Rockville, MD, about allegations of noncompliance. -
Community research requires compromise
IRBs increasingly will have to adjust to collaborative approaches in research, including working with community partners and other stakeholders, experts say. -
FDA’s draft guidance clarifies IRB roles
The Food and Drug Administration (FDA) has received many lengthy comments expressing concern about its recent draft guidance for IRBs, investigators, and sponsors regarding assessing the qualifications of investigators. -
University creates new model for shared review
In June 2011, representatives from various IRBs and federal regulatory bodies met to discuss the development of a new model to improve the multisite study model. -
Central vs. local IRB for multisite research
The research oversight system, says a University of North Carolina at Chapel Hill researcher, has not evolved to keep up with the volume and complexity of the research it oversees. -
FDA: Obtain IND for C. diff treatment
The Food and Drug Administration (FDA) has now said that clinicians wishing to perform a fecal transplant for treatment of Clostridium difficile will have to obtain an investigational new drug (IND) application.